Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
United StatesIPO:
18 July 2019Website:
http://www.phreesia.comNext earnings report:
06 September 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
PHR Latest News
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Phreesia, Inc. ("Phreesia") (NYSE:PHR) concerning possible violations of federal securities laws. Phreesia issued a press release on May 30, 2024, announcing financial results for the first quarter of its fiscal year 2025.
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. ("Phreesia" or the "Company") (NYSE: PHR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Phreesia, Inc. ("Phreesia") (NYSE:PHR) concerning possible violations of federal securities laws. Phreesia issued a press release on May 30, 2024, announcing financial results for the first quarter of its fiscal year 2025.
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Phreesia, Inc. ("Phreesia") (NYSE:PHR) concerning possible violations of federal securities laws. Phreesia issued a press release on May 30, 2024, announcing financial results for the first quarter of its fiscal year 2025.
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE: PHR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Phreesia, Inc. ("Phreesia") (NYSE:PHR) concerning possible violations of federal securities laws. Phreesia issued a press release on May 30, 2024, announcing financial results for the first quarter of its fiscal year 2025.
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. ("Phreesia" or the "Company") (NYSE:PHR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE: PHR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, NY / ACCESSWIRE / June 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phreesia, Inc. ("Phreesia" or "the Company") (NYSE:PHR). Investors who purchased Phreesia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PHR.
What type of business is Phreesia?
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
What sector is Phreesia in?
Phreesia is in the Healthcare sector
What industry is Phreesia in?
Phreesia is in the Health Information Services industry
What country is Phreesia from?
Phreesia is headquartered in United States
When did Phreesia go public?
Phreesia initial public offering (IPO) was on 18 July 2019
What is Phreesia website?
https://www.phreesia.com
Is Phreesia in the S&P 500?
No, Phreesia is not included in the S&P 500 index
Is Phreesia in the NASDAQ 100?
No, Phreesia is not included in the NASDAQ 100 index
Is Phreesia in the Dow Jones?
No, Phreesia is not included in the Dow Jones index
When does Phreesia report earnings?
The next expected earnings date for Phreesia is 06 September 2024